<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40828313</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1969-6213</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>16</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology</Title><ISOAbbreviation>EuroIntervention</ISOAbbreviation></Journal><ArticleTitle>Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial.</ArticleTitle><Pagination><StartPage>910</StartPage><EndPage>920</EndPage><MedlinePgn>910-920</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4244/EIJ-D-24-01065</ELocationID><ELocationID EIdType="pii" ValidYN="Y">EIJ-D-24-01065</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prolonged lipid-lowering therapy has demonstrated its ability to induce plaque regression and improve the plaque morphology of mild atherosclerotic lesions.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">This trial aimed to assess the short-term effect of evolocumab in addition to high-intensity statin therapy (HIST) on relevant non-culprit coronary artery lesions using fractional flow reserve (FFR) measurements and multimodality intracoronary imaging.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with an acute coronary syndrome (ACS) and relevant multivessel disease were randomised to receive either evolocumab or placebo for 12 weeks in addition to HIST. Patients underwent serial FFR and intravascular ultrasound (IVUS)-near-infrared spectroscopy imaging of a non-culprit vessel. The primary endpoints were the differences in the change in FFR and in the maximum lipid core burden index within any 4 mm segment (maxLCBI<sub>4mm</sub>). The secondary endpoints were the differences in the change in IVUS-derived atheroma volume parameters.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 150 patients (mean age 64.2&#xb1;8.5 years; 27 [18.0%] female) randomised to evolocumab (n=74) or placebo (n=76), 143 underwent follow-up coronary angiography. After 12 weeks of treatment, the adjusted mean change in FFR was 0.00 (95% confidence interval [CI]: -0.02 to 0.02) with evolocumab versus 0.01 (95% CI: -0.01 to 0.03) with placebo (adjusted mean difference: -0.01, 95% CI: -0.03 to 0.01; p=0.6). The adjusted mean change in the maxLCBI<sub>4mm</sub> was -27.8 (95% CI: -72.2 to 16.6) for evolocumab-treated patients versus -35.6 (95% CI: -82.5 to 11.4) for placebo-treated patients (adjusted mean difference: 7.8, 95% CI: -40.9 to 56.4; p=0.8). No between-group differences in any IVUS-derived parameter were found.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with ACS and relevant non-culprit coronary artery lesions, the addition of evolocumab to HIST for 12 weeks, compared to placebo, did not result in improvement of FFR or maxLCBI<sub>4mm</sub>. (ClinicalTrials.gov: NCT04141579).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mensink</LastName><ForeName>Frans B</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Los</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reda Morsy</LastName><ForeName>Mohamed M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Assiut University, Asyut, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oemrawsingh</LastName><ForeName>Rohit M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Albert Schweitzer Ziekenhuis, Dordrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Birgelen</LastName><ForeName>Clemens</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ijsselmuiden</LastName><ForeName>Alexander J J</ForeName><Initials>AJJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Amphia Hospital, Breda, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Maastricht University Medical Center, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meuwissen</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Amphia Hospital, Breda, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Jin M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Albert Schweitzer Ziekenhuis, Dordrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Amphia Hospital, Breda, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Wijk</LastName><ForeName>Diederik F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Noordwest ziekenhuisgroep locatie Alkmaar, Alkmaar, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smits</LastName><ForeName>Pieter C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paradies</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Wijk</LastName><ForeName>Dirk J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Haaglanden Medisch Centrum, the Hague, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rai</LastName><ForeName>Himanshu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Cate</LastName><ForeName>Tim J F</ForeName><Initials>TJF</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camaro</LastName><ForeName>Cyril</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damman</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Nunen</LastName><ForeName>Lokien X</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitriu-Leen</LastName><ForeName>Aukelien C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Wely</LastName><ForeName>Marleen H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cetinyurek-Yavuz</LastName><ForeName>Aysun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Royen</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Geuns</LastName><ForeName>Robert-Jan M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04141579</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>EuroIntervention</MedlineTA><NlmUniqueID>101251040</NlmUniqueID><ISSNLinking>1774-024X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>LKC0U3A8NJ</RegistryNumber><NameOfSubstance UI="C577155">evolocumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091362">PCSK9 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054058" MajorTopicYN="Y">Acute Coronary Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="Y">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003331" MajorTopicYN="N">Coronary Vessels</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053805" MajorTopicYN="N">Fractional Flow Reserve, Myocardial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091362" MajorTopicYN="Y">PCSK9 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058226" MajorTopicYN="Y">Plaque, Atherosclerotic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018084" MajorTopicYN="N">Ultrasonography, Interventional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071449" MajorTopicYN="N" AutoHM="Y">Proprotein Convertase 9</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>M.M. Reda Morsy reports funding from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Education and Training Grants Programme. R.M. Oemrawsingh reports speaker fees from Abbott and Terumo. C. von Birgelen reports institutional research grants from Abbott, Boston Scientific, Biotronik, and Medtronic, outside the current study. A.J.J. IJsselmuiden reports institutional fees from Medtronic, Meril Life Sciences, and Abbott; and consulting fees from Meril Life Sciences, Angiocare, Abbott, Philips, and Translumina. P.C. Smits reports institutional research grants from Abbott and SMT; and consulting or speaker fees from Abbott, MicroPort, SMT, and Terumo; he participates on a data safety monitoring board or advisory board of the LEGACY trial, PROCTOR trial, and on the global coronary advisory board of Abbott; he is a minor shareholder of the European Cardiovascular Research Center. V. Paradies reports institutional grants from Abbott; and personal consulting or speaker fees from Abbott, Boston Scientific, Elixir, and Novo Nordisk; she participates on advisory boards or committees of Boston Scientific, EAPCI Chair Congress Committee, and is an ESC CPC member. C. Camaro reports institutional speaker fees from AstraZeneca and from regional interventional cardiology meetings. P. Damman reports research grants from Abbott, Philips, Pie Medical Imaging, and AstraZeneca; and consulting fees from Philips and Abbott. M.H. van Wely reports consulting fees from Boston Scientific and Abbott. R.A. Byrne reports grants received by the institutions of employment for research or education from Abbott, Biosensors, Boston Scientific, and Translumina, without impact on personal remuneration, and he does not accept personal payments from the medical device or pharmaceutical industry. N. van Royen reports research grants from Biotronik, Abbott, Medtronic, and Philips; and speaker fees from Abbott, RainMed, MicroPort, and Bayer. R.-J.M. van Geuns reports consulting and speaker fees from Abbott and AstraZeneca; and has received institutional research grants from Amgen, InfraRedx, AstraZeneca, and Sanofi. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>14</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>19</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40828313</ArticleId><ArticleId IdType="pmc">PMC12337765</ArticleId><ArticleId IdType="doi">10.4244/EIJ-D-24-01065</ArticleId><ArticleId IdType="pii">EIJ-D-24-01065</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">25586123</ArticleId></ArticleIdList></Reference><Reference><Citation>Varenhorst C, Hasvold P, Johansson S, Janzon M, Albertsson P, Leosdottir M, Hambraeus K, James S, Jernberg T, Svennblad B, Lagerqvist B. Culprit and Nonculprit Recurrent Ischemic Events in Patients With Myocardial Infarction: Data From SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). J Am Heart Assoc. 2018;7:e007174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5778965</ArticleId><ArticleId IdType="pubmed">31913732</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlinge D, Maehara A, Ben-Yehuda O, B&#xf8;tker HE, Maeng M, Kj&#xf8;ller-Hansen L, Engstr&#xf8;m T, Matsumura M, Crowley A, Dressler O, Mintz GS, Fr&#xf6;bert O, Persson J, Wiseth R, Larsen AI, Okkels Jensen, Nordrehaug JE, Bleie &#xd8;, Omerovic E, Held C, James SK, Ali ZA, Muller JE, Stone GW PROSPECT II Investigators. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet. 2021;397:985&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">33714389</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone GW, Maehara A, Lansky AJ, de Bruyne, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">21247313</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11277825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">15007110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kini AS, Baber U, Kovacic JC, Limaye A, Ali ZA, Sweeny J, Maehara A, Mehran R, Dangas G, Mintz GS, Fuster V, Narula J, Sharma SK, Moreno PR. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62:21&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23644090</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xe4;ber L, Taniwaki M, Zaugg S, Kelb&#xe6;k H, Roffi M, Holmvang L, Noble S, Pedrazzini G, Moschovitis A, L&#xfc;scher TF, Matter CM, Serruys PW, J&#xfc;ni P, Garcia-Garcia HM, Windecker S IBIS 4 (Integrated Biomarkers and Imaging Study-4) Trial Investigators (NCT00962416) Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Eur Heart J. 2015;36:490&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">25182248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16533939</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">22085316</ArticleId></ArticleIdList></Reference><Reference><Citation>Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, H&#xe4;ner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, R&#xe4;ber L, Heg D, Mach F. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74:2452&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">31479722</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Bujas-Bobanovic M, Diaz R, Fazio S, Fras Z, Goodman SG, Harrington RA, Jukema JW, Manvelian G, Pordy R, Ray KK, Scemama M, White HD, Steg PG ODYSSEY OUTCOMES Investigators. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. Eur Heart J. 2023;44:1408&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10119028</ArticleId><ArticleId IdType="pubmed">36879424</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xe4;ber L, Ueki Y, Otsuka T, Losdat S, H&#xe4;ner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns, Ondracek AS, Radu Juul, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstr&#xf8;m T, Lang IM, Koskinas KC PACMAN-AMI collaborators. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327:1771&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8978048</ArticleId><ArticleId IdType="pubmed">35368058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JR, Hermanides RS, Wang B, Wang H, Butters J, Di Giovanni, Jones S, Pompili G, Psaltis PJ. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022;15:1308&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">35431172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316:2373&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">27846344</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonino PA, De Bruyne, Pijls NH, Siebert U, Ikeno F, van' t, Klauss V, Manoharan G, Engstr&#xf8;m T, Oldroyd KG, Ver Lee, MacCarthy PA, Fearon WF FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19144937</ArticleId></ArticleIdList></Reference><Reference><Citation>Mensink FB, Los J, Oemrawsingh RM, von Birgelen, Ijsselmuiden A, Meuwissen M, Cheng JM, van Wijk, Smits PC, Paradies V, van der, Rai H, Ten Cate, Camaro C, Damman P, van Nunen, Dimitriu-Leen AC, van Wely, Cetinyurek-Yavuz A, Byrne RA, van Royen, van Geuns. Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: Rationale and design of the randomized FITTER trial. Heliyon. 2024;10:e38077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11489145</ArticleId><ArticleId IdType="pubmed">39430462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CH, Hwang J, Kim IC, Cho YK, Park HS, Yoon HJ, Kim H, Han S, Hur SH, Kim KB, Kim JY, Chung JW, Lee JM, Doh JH, Shin ES, Koo BK, Nam CW. Effect of Atorvastatin on Serial Changes in Coronary Physiology and Plaque Parameters. JACC Asia. 2022;2:691&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9700034</ArticleId><ArticleId IdType="pubmed">36444331</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;r S, Kavaliauskaite R, Otsuka T, Ueki Y, H&#xe4;ner JD, Siontis GCM, Stortecky S, Shibutani H, Temperli F, Kaiser C, Iglesias JF, Jan van, Daemen J, Spirk D, Engstr&#xf8;m T, Lang I, Windecker S, Koskinas KC, Losdat S, R&#xe4;ber L. Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial. EuroIntervention. 2023;19:e286&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10333923</ArticleId><ArticleId IdType="pubmed">37341586</ArticleId></ArticleIdList></Reference><Reference><Citation>van der, Janssens GN, de Waard, Everaars H, Broyd CJ, Beijnink CWH, van de, Nijveldt R, Cook CM, Petraco R, Ten Cate, von Birgelen, Escaned J, Davies JE, van Leeuwen, van Royen. Temporal Changes in Coronary Hyperemic and Resting Hemodynamic Indices in Nonculprit Vessels of Patients With ST-Segment Elevation Myocardial Infarction. JAMA Cardiol. 2019;4:736&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613339</ArticleId><ArticleId IdType="pubmed">31268466</ArticleId></ArticleIdList></Reference><Reference><Citation>Biesbroek PS, Amier RP, Teunissen PFA, Hofman MBM, Robbers LFHJ, van de, Beek AM, van Rossum, van Royen, Nijveldt R. Changes in remote myocardial tissue after acute myocardial infarction and its relation to cardiac remodeling: A CMR T1 mapping study. PLoS One. 2017;12:e0180115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482488</ArticleId><ArticleId IdType="pubmed">28644903</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Herck, Carlier SG, Claeys MJ, Haine SE, Gorissen P, Miljoen H, Bosmans JM, Vrints CJ. Coronary microvascular dysfunction after myocardial infarction: increased coronary zero flow pressure both in the infarcted and in the remote myocardium is mainly related to left ventricular filling pressure. Heart. 2007;93:1231&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2000925</ArticleId><ArticleId IdType="pubmed">17395671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo YS, Moon H, Park K. Different Microcirculation Response Between Culprit and Non-Culprit Vessels in Patients With Acute Coronary Syndrome. J Am Heart Assoc. 2020;9:e015507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660838</ArticleId><ArticleId IdType="pubmed">32410526</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, Barbato E, Hamilos M, Mangiacapra F, Heyndrickx GR, Wijns W, Pijls NH, De Bruyne. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2010;3:1274&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">21232721</ArticleId></ArticleIdList></Reference><Reference><Citation>Musto C, De Felice, Rigattieri S, Chin D, Marra A, Nazzaro MS, Cifarelli A, Violini R. Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study. Am Heart J. 2017;193:63&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29129256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka T, Morishita T, Uzui H, Sato Y, Shimizu T, Miyoshi M, Yamaguchi J, Shiomi Y, Ikeda H, Tama N, Hasegawa K, Ishida K, Tada H. Very short-term effects of a single dose of a proprotein convertase subtilisin/kexin 9 inhibitor before percutaneous coronary intervention: A single-arm study. Atherosclerosis. 2024;399:118581.</Citation><ArticleIdList><ArticleId IdType="pubmed">39277430</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K, Yonetsu T, Kim SJ, Xing L, Lee H, McNulty I, Yeh RW, Sakhuja R, Zhang S, Uemura S, Yu B, Mizuno K, Jang IK. Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging. 2012;5:433&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22679059</ArticleId></ArticleIdList></Reference><Reference><Citation>Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">3574413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>